Meiji Seika Pharma Co., Ltd.

Overview

Meiji Seika Pharma Co., Ltd., is a leading pharmaceutical company based in Japan, specializing in the development and marketing of pharmaceutical drugs. It is a subsidiary of Meiji Holdings Co., Ltd., focusing on providing innovative solutions in infectious disease treatment and central nervous system therapies.

Therapeutic areas

API / Drug Master Files

Meiji Seika Pharma Co., Ltd. holds 3 active (7 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• ME3183Active2018-11-21
• DAUNORUBICIN HYDROCHLORIDE (DRUG SUBSTANCE)Active1998-09-01
• DOXORUBICIN HYDROCHLORIDE DRUG SUBSTANCEActive1998-04-30
• ME1111 DRUG SUBSTANCEInactive2012-11-12
• ARBEKACIN FREE BASE DRUG SUBSTANCE (ME1100)Inactive2012-06-08
• ARBEKACIN SULFATE DRUG SUBSTANCEInactive2011-09-30
• CEFDITOREN PIVOXIL DRUG SUBSTANCEInactive2004-06-22

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to Meiji Seika Pharma Co., Ltd. in our records. PharmaTek screens the full directory against live FDA enforcement data.